X0306 4 2017-11-21 0 0001604950 scPharmaceuticals Inc. SCPH 0001055951 ORBIMED ADVISORS LLC C/O SCPHARMACEUTICALS INC 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01830 0 0 1 0 0001682115 OrbiMed Capital GP VI LLC 601 LEXINGTON AVENUE (AT 53RD STREET) 54TH FLOOR NEW YORK NY 10022-4629 0 0 1 0 0001055949 ISALY SAMUEL D 601 LEXINGTON AVENUE (AT 53RD STREET) 54TH FLOOR NEW YORK NY 10022-4629 0 0 1 0 Common Stock 2017-11-21 4 C 0 2576532 A 2576532 I See Footnotes Common Stock 2017-11-21 4 P 0 833333 14.00 A 3409865 I See Footnotes Series B Preferred Stock 2017-11-21 4 C 0 18500000 0.00 D Common Stock 2576532 0 I See Footnotes Represents the total number of shares of Common Stock received by OrbiMed Private Investments VI, L.P. ("OPI VI"), upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. Samuel D. Isaly, a natural person, is a managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP VI, Advisors and Mr. Isaly may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. This report on Form 4 is jointly filed by GP VI, Advisors and Isaly. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date. /s/ Courtney Gaughan, Attorney-in-Fact 2017-11-21